Ceribell jumps on FDA clearance of brain monitoring device

Shares of medical device maker Ceribell CBLL.O rise 10.5% to $22.33

Co says the U.S. FDA cleared its screening and monitoring device to assist in diagnosing patients at risk for both seizures and delirium

Delirium is a potential indicator for life-threatening conditions and is defined as a mental state characterized by confusion, disorientation, and reduced awareness of surroundings

Ceribell's device uses an AI-powered software algorithm to analyze brain activity that is associated with delirium

Up to last close, stock down 21.9% YTD